Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Behavior Therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    173 result(s) found for: Behavior Therapy. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2009-011115-20 Sponsor Protocol Number: NordLOTS protocol step 3 1.1 Start Date*: 2009-08-14
    Sponsor Name:The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP)
    Full Title: Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the "Expert Clinical Guidelines". The study is performed with no sponsor from phar...
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049596 Obsession LLT
    9.1 10010219 Compulsions LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing) NO (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004613-34 Sponsor Protocol Number: NordLOTS protocol 1.4 Start Date*: 2008-03-14
    Sponsor Name:The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP)
    Full Title: Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the "Expert Clinical Guidelines". The study is performed with no sponsor from phar...
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049596 Obsession LLT
    9.1 10010219 Compulsions LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002207-13 Sponsor Protocol Number: NRA1280023 Start Date*: 2006-06-29
    Sponsor Name:Dept. Child & Adolescent Psychiatry Univ. Freiburg
    Full Title: Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial
    Medical condition: conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002251-33 Sponsor Protocol Number: 01 Start Date*: 2006-10-10
    Sponsor Name:University of Vienna
    Full Title: Hypoxia Imaging with the novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic impact in Cervical Cancer .
    Medical condition: Twenty-five patients with cervical carcinoma (T2Nx or TxN1) will be included in the present study. In addition to the routine pre-therapeutical staging of cervical cancer, 18FAZA PET will be perfor...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004128-32 Sponsor Protocol Number: KZM-PSMA-01 Start Date*: 2017-12-01
    Sponsor Name:Fakultní nemocnice Plzeň
    Full Title: Imaging of the prostate tumors using PET/CT and PET/MRI with the ligand of the prostatic specific membrane antigene 68Ga-PSMA-11
    Medical condition: prostatic carcinoma higly suspected or its staging or restaging
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005331-23 Sponsor Protocol Number: SCOUT-015 Start Date*: 2022-06-20
    Sponsor Name:Radius Pharmaceuticals, Inc.
    Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndrome
    Medical condition: Hyperphagia related behavior associated with Prader-Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020710 Hyperphagia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004981-37 Sponsor Protocol Number: BMXBAR01 Start Date*: 2022-01-19
    Sponsor Name:Helse Bergen HF
    Full Title: Benzodiazepine maintenance treatment for patients with benzodiazepine dependence undergoing opioid agonist therapy (BMX-BAR)
    Medical condition: Benzodiazepine dependence
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019930-28 Sponsor Protocol Number: 31116 Start Date*: 2011-03-09
    Sponsor Name:Accare
    Full Title: The effectiveness of Parent-Child Interaction Therapy versus methylphenidate in preschool children with ADHD and disruptive behavior problems with insufficient improvement through Parent Management...
    Medical condition: ADHD ODD
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064104 ADHD LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001790-25 Sponsor Protocol Number: FP01C-13-001 Start Date*: 2014-09-01
    Sponsor Name:Foresee Pharmaceuticals Co., Ltd.
    Full Title: An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate Carcinoma
    Medical condition: Advanced Prostate Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) SK (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-002699-83 Sponsor Protocol Number: 31-08-248 Start Date*: 2009-01-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) HU (Completed) AT (Completed) EE (Completed) DK (Prematurely Ended) FR (Completed) GB (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005088-82 Sponsor Protocol Number: CAFQ056A2204 Start Date*: 2008-05-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of mul...
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017324 Fragile X syndrome PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005387-22 Sponsor Protocol Number: ACP-103-069 Start Date*: 2022-06-27
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
    Medical condition: Treatment of irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) HU (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000256-33 Sponsor Protocol Number: Ra-P-OCD-01 Start Date*: 2019-06-27
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement
    Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000195-15 Sponsor Protocol Number: P4-SAF-302 Start Date*: 2018-12-27
    Sponsor Name:Lysogene SA
    Full Title: An Open-Label, Single-Arm, Multicenter Study of Intracerebral Administration of Adeno-Associated Viral Vectors Serotype rh10 Carrying the Human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA for the...
    Medical condition: Mucopolysaccharidosis Type IIIA
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) NL (Temporarily Halted) DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2008-002675-27 Sponsor Protocol Number: 31-07-246 Start Date*: 2009-05-11
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Ma...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001916-37 Sponsor Protocol Number: MATRICS_WP6-1 Start Date*: Information not available in EudraCT
    Sponsor Name:RADBOUD UNIVERSITY MEDICAL CENTER
    Full Title: The neuropsychological characterization of aggressive behaviour in children and adolescents with Conduct Disorder or Oppositional Defiant Disorder (CD/ODD)
    Medical condition: Aggressive behavior in children and adolescents with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10037183 Psychic disturbance LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004692-36 Sponsor Protocol Number: VAR/01/011 Start Date*: 2011-11-30
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: COMBIVAR. Randomized double-blind trial of two parallel groups design to evaluate the efficacy of smoking cessation with combined (varenicline plus nicotine patches) versus monotherapy (varenicline)
    Medical condition: NICOTINE DEPENDENCE.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10032707 Other specified drug dependence, continuous use LLT
    14.0 10037175 - Psychiatric disorders 10012336 Dependence addictive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002485-39 Sponsor Protocol Number: TAK-935-18-001(OV935)Amendment1 Start Date*: 2019-06-14
    Sponsor Name:Ovid Therapeutics, Inc.
    Full Title: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEP...
    Medical condition: developmental and epileptic encephalopathies
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2010-019712-20 Sponsor Protocol Number: DCSP1 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Oslo, Institute of Clinical Dentistry
    Full Title: D-CYCLOSERINE ENHANCEMENT OF EXPOSURE TREATMENT OF DENTALLY FEARFUL AND AVOIDANT CHILDREN. A PILOT STUDY
    Medical condition: Avoidance of dental care because of dental anxiety often result in reduced dental health and need for sedation or treatment in general anesthesia. Treatment of dental anxiety is time consuming and ...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002819-28 Sponsor Protocol Number: OCDDCS001 Start Date*: 2012-04-12
    Sponsor Name:Stockholms Läns Landsting
    Full Title: Internet-based cognitive behavior therapy in combination with D-Cycloserine for Obsessive Compulsive Disorder: A double blinded randomized controlled trial
    Medical condition: Obsessive Compulsive disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:30:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA